RLYB
Rallybio CorpKey Statistics
About Rallybio Corp
Rallybio Corp is a clinical-stage biotechnology firm focused on developing innovative therapies for rare diseases, particularly in the fields of immunology and hematology. The company boasts a robust pipeline of biologic drug candidates that are advancing through various clinical trials, supported by a seasoned management team with deep industry knowledge. By leveraging strategic partnerships, Rallybio enhances its capacity to deliver transformative treatments in underserved therapeutic areas, underscoring its commitment to improving patient outcomes. With its focused approach, Rallybio is well-positioned to make significant contributions to the healthcare landscape while progressing towards commercial viability.
Fundamentals
| Revenue (TTM) | 858,000 |
| Gross Profit (TTM) | $-17.54M |
| EBITDA | $-30.36M |
| Operating Margin | -4119.00% |
| Return on Equity | -15.00% |
| Return on Assets | -33.80% |
| Revenue/Share (TTM) | $0.15 |
| Book Value | $9.50 |
| Price-to-Book | 1.69 |
| Price-to-Sales (TTM) | 98.06 |
| EV/Revenue | 44.38 |
| EV/EBITDA | -1.41 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $5.30M |
| Float | $3.16M |
| % Insiders | 4.15% |
| % Institutions | 96.07% |
Historical Volatility
Volatility is currently contracting